AP NEWS

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

November 16, 2018

MIRAMAR, Fla.--(BUSINESS WIRE)--Nov 16, 2018--Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that it will hold an investor conference call at 9:00 a.m. Eastern time on Monday, December 3, 2018. The purpose of the conference call will be to provide investors with an update on the Company’s initiatives and strategic plans. Webcast and dial-in information for the call will be announced next week.

Generex President & Chief Executive Officer Joseph Moscato stated: “I will look forward to addressing my fellow stockholders following the November 30 payment of the common stock dividend, along with the rest of the Generex management team, to provide a comprehensive update on your Company’s recent successes and your management team’s near-term and longer-term objectives. We will discuss our recent acquisitions, our growth strategies for NuGenerex Distribution Solutions, as well as the immuno-oncology, diagnostics, and drug delivery platforms.”

About Generex Biotechnology Corporation

Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development.

The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.

On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care.

Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary buccal administration of insulin.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181116005079/en/

CONTACT: Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

800-391-6755 Extension 222

investor@generex.com

Russo Partners

Investor / Media Contacts:

Alex Fudukidis

(646) 942-5632

alex.fudukidis@russopartnersllc.com

Caroline Cunningham

(212) 845-4292

Caroline.Cunningham@russopartnersllc.com

KEYWORD: UNITED STATES NORTH AMERICA FLORIDA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL DIABETES

SOURCE: Generex Biotechnology Corporation

Copyright Business Wire 2018.

PUB: 11/16/2018 09:00 AM/DISC: 11/16/2018 09:01 AM

http://www.businesswire.com/news/home/20181116005079/en

AP RADIO
Update hourly